Abstract YO23
Case summary
Soft tissue Giant cell tumor presented as Nasopharyngeal mass : A case Report
ABSTRACT:
Background:
Primary soft tissue giant cell tumors are exceedingly rare. These often present in the elderly and are mostly noted on the extremities. Morphologically, these tumors resemble their osseous counterparts but sequencing studies have suggested that these two may be genetically distinct. Surgical extirpation remains standard of treatment; but for those with unresectable disease treatment options are less clear. For these patients, the use of bisphosphonates and RANK-L directed biologic therapy have been reported in the literature.
Case presentation:
A 30 year old male consulted at our medical oncology clinic with the chief complaint of diplopia. Magnetic resonance imaging (MRI) of the head revealed an enhancing soft tissue mass at the nasopharyngeal wall measuring 5.8x5.5x5.1cm extending anteriorly at the posterior margin of the nasal cavity, both parasellar regions, leptomeningeal region of the medial aspect of both middle cranial fossa, and infiltrating into the clivus. No distant metastasis was seen. Punch biopsy of this nasopharyngeal mass favored a giant cell tumor. Immunohistochemical staining was done with the following results: Cytokeratin negative, CD68 positive, and Vimentin positive, all consistent with giant cell tumor. Due to its location, the tumor was regarded to be unresectable. Zoledronic acid was given once every 28 days for 3 months. Cranial CT scan done after three months of treatment revealed an enhancing nasopharyngeal mass measuring 6.0x5.0x4.0cm with intracranial extension. At this time despite demonstrating stable disease, the patient was noted to have worsening of symptoms and was then shifted to Denosumab.
Conclusion:
We have reported a case of a nasopharyngeal giant cell tumor, which is an uncommon presentation of a rare soft tissue tumor. While surgery is the preferred treatment for this disease, the location of this tumor precluded resection. This has prompted the decision to employ systemic treatment with Zoledronic acid and subsequently Denosumab for this patient.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract